Close menu




September 30th, 2025 | 07:40 CEST

Antimony Resources, Rheinmetall, Novo Nordisk – Something is in the air!

  • Mining
  • antimony
  • Defense
  • Biotechnology
Photo credits: pixabay.com

Sufficient access to raw materials is crucial for any economy. The EU has compiled a list of 34 critical raw materials. How critical a raw material is classified depends on two parameters: "economic importance" and "supply risk." This list also includes a little-known but very important metalloid – antimony. The price of antimony skyrocketed at the end of 2024 in the wake of China's export ban. There are still exciting investment opportunities in this area.

time to read: 2 minutes | Author: Carsten Mainitz
ISIN: ANTIMONY RESOURCES CORP | CA0369271014 , RHEINMETALL AG | DE0007030009 , NOVO NORDISK A/S | DK0062498333

Table of contents:


    Sébastien Plouffe, CEO, Founder and Director, Defence Therapeutics Inc.
    "[...] Defence will continue to develop its Antibody Drug Conjugates "ADC" and its radiopharmaceuticals programs, which are currently two of the hottest products in demand in the pharma industries where significant consolidations and take-overs occurred. [...]" Sébastien Plouffe, CEO, Founder and Director, Defence Therapeutics Inc.

    Full interview

     

    Antimony Resources – Still flying under the radar of investors

    Antimony is versatile and in high demand: its applications as a flame retardant, in photovoltaics, defense, semiconductors, and energy storage highlight its importance. As with many other critical metals and rare earths, China dominates global supply. At the end of last year, the country imposed a global export ban. This shines a spotlight on future producers, such as Antimony Resources.

    The Canadians have the option to acquire the Bald Hill property in southern New Brunswick, Canada. Previous drilling has identified antimony over a length of more than 700 m and a depth of 400 m with an average thickness of over 3 m and a grade of 3% to 4% antimony (Sb). This distinguishes Bald Hill as a first-class, high-grade antimony deposit.

    The current drilling program, which could give the stock a significant boost, is divided into several phases. A total of at least 6,000 meters of drilling is to be completed. Phase 1 at Bald Hill has already delivered good results. Significant high-grade antimony deposits were intersected in over 75% of the drill holes. The previously defined main mineralization zone was also significantly expanded.

    The Company has now announced the start of the second phase of its drilling program, with two main priorities. The first is to extend the known antimony-bearing mineralization to the north and south and to expand the mineralization at depth. This trend has already been successfully demonstrated in Phase 1.

    The second priority is to drill at locations that demonstrate a connection between widely separated mineralization zones. The aim is to determine whether the mineralization is sufficiently continuous and whether sufficient data is available.

    Rheinmetall – Above the EUR 2000 mark for the first time

    As mentioned above, antimony plays an important role in the defense industry. This semi-metal increases the hardness and stability of lead and is therefore essential in the manufacture of ammunition and armor. Antimony is also used in high-tech weapons, night vision devices, and infrared sensors.

    German defense stocks continued their rally at the beginning of the week, reaching new all-time highs. Rheinmetall shares climbed slightly above the EUR 2,000 mark for the first time. Although the shares have already increased twentyfold since the start of the war in Ukraine, analysts at UBS and mwb research still see room for growth up to EUR 2,500.

    The enormous demand for weapon systems and ammunition continues to swell order books. The DAX-listed company recently announced that it would be supplying ammunition to Eastern Europe as a subcontractor to a company commissioned by the US government. The total value of the order is in the mid three-digit million range.

    Novo Nordisk – Negative analyst opinion weighs on the stock in the short term

    A significant downgrade by Morgan Stanley to "Underweight", coupled with a price target capped at EUR 40, weighed on the stock in the short term. Analysts expect minimal growth in revenue and profits next year and point to the Danish company's challenging competitive position.

    The shares are currently trading at around EUR 47 and have already priced in many negative factors. At first glance, the stock appears undervalued historically, but growth remains subdued. Investors are not missing out on anything yet and can monitor developments from the sidelines.


    If Antimony Resources' current drilling program proves successful, as initial data suggests, this could give the share price a significant boost. The market capitalization is just CAD 11 million. Rheinmetall is benefiting from sustained high demand and still has room for growth despite reaching an all-time high. A lot of negative factors are already priced into Novo Nordisk's share price.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Carsten Mainitz

    The native Rhineland-Palatinate has been a passionate market participant for more than 25 years. After studying business administration in Mannheim, he worked as a journalist, in equity sales and many years in equity research.

    About the author



    Related comments:

    Commented by André Will-Laudien on October 21st, 2025 | 07:45 CEST

    AI boom and DAX fireworks! Another 100% with NetraMark, Bayer, and Novo Nordisk

    • AI
    • Biotechnology
    • Biotech
    • Pharma

    Savvy investors are already taking notice! Artificial intelligence is revolutionizing drug research and radically reducing development costs. Algorithms are discovering molecular patterns that even the most experienced researchers would overlook, thus accelerating the path from laboratory to patient. Whether in oncology, rare diseases, or metabolic disorders, big data-driven models now enable more precise drug predictions and more realistic simulations of clinical outcomes. Those who understand AI can profit handsomely from the next biotech boom. You just have to muster the courage to finally get involved!

    Read

    Commented by Carsten Mainitz on October 21st, 2025 | 07:40 CEST

    Power Metallic Mines, RENK, BYD – An explosive combination! And the winners are?

    • Mining
    • Copper
    • Nickel
    • Gold
    • CriticalMetals
    • Electromobility
    • Defense

    Many topics are dominating the headlines. Peace in Gaza – and soon in Ukraine? This prospect initially put a significant damper on defense stocks – but only temporarily. After just a few days of correction, prices are already rising again. Gold at an all-time high is another major topic being covered in the media. Meanwhile, the geopolitical shifts we were reluctant to acknowledge for far too long are now catching up with many companies: China is cutting the world off from critical raw materials and rare earths. Read here to find out how investors can identify promising high-potential opportunities in this constellation.

    Read

    Commented by André Will-Laudien on October 21st, 2025 | 07:35 CEST

    Gold USD 4,300 and Silver USD 53 – Buying frenzy at Silver North, First Majestic, Nel ASA, and JinkoSolar

    • Mining
    • Silver
    • Gold
    • renewableenergies
    • Solar
    • Energy

    Silver has been shorted by many investment banks for several years because sufficient supply was available from Mexico and other producing countries. The tide has turned. Over the past 12 months, the precious metal has caught up with its big brother gold, gaining 54%. There are several reasons for the scarcity-driven rally: there are only around 250 active silver mines worldwide, compared to around 1,400 gold mines. In addition, silver has massively expanded its importance as an industrial metal: it is indispensable in high-tech, e-mobility, defense, and medical technology. As a result, less and less physical silver is available to investors, while inventories on the futures markets continue to decline. Now is the time to take a position in silver. Alongside industry giants such as First Majestic, Silver North is among the most promising beneficiaries of the new silver boom.

    Read